Compared to control cells, doubling of shSpry3-treated cells was reduced from 0.58 to 0.50 doublings per day, substantiating an oncogenic effect of Spry3 in brain cancer (Figure 6D). The gene discussed is SPRY3; the disease is brain cancer.